WO2003051911A3 - Polypeptides et polynucleotides gmg-5 et utilisations de ceux-ci - Google Patents

Polypeptides et polynucleotides gmg-5 et utilisations de ceux-ci Download PDF

Info

Publication number
WO2003051911A3
WO2003051911A3 PCT/IB2002/004806 IB0204806W WO03051911A3 WO 2003051911 A3 WO2003051911 A3 WO 2003051911A3 IB 0204806 W IB0204806 W IB 0204806W WO 03051911 A3 WO03051911 A3 WO 03051911A3
Authority
WO
WIPO (PCT)
Prior art keywords
metabolic
disorders
gmg
polypeptides
polynucleotides
Prior art date
Application number
PCT/IB2002/004806
Other languages
English (en)
Other versions
WO2003051911A2 (fr
Inventor
Hiroaki Tanaka
Deno Dialynas
Aaron Scalia
Original Assignee
Genset Sa
Hiroaki Tanaka
Deno Dialynas
Aaron Scalia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genset Sa, Hiroaki Tanaka, Deno Dialynas, Aaron Scalia filed Critical Genset Sa
Priority to AU2002339697A priority Critical patent/AU2002339697A1/en
Publication of WO2003051911A2 publication Critical patent/WO2003051911A2/fr
Publication of WO2003051911A3 publication Critical patent/WO2003051911A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention s'inscrit dans le domaine de la recherche sur le métabolisme. Les troubles du métabolisme, tels que l'obésité, constituent un problème de santé public grave et étendu. On a identifié des polypeptides GMG-5 qui se révèlent être bénéfiques pour le traitement des troubles du métabolisme. Ces composés permettent de réduire la masse corporelle et ils permettent de traiter les maladies et les troubles liés au métabolisme, parmi lesquels l'hyperlipidémies, l'athérosclérose, les diabètes et l'hypertension.
PCT/IB2002/004806 2001-12-19 2002-10-29 Polypeptides et polynucleotides gmg-5 et utilisations de ceux-ci WO2003051911A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002339697A AU2002339697A1 (en) 2001-12-19 2002-10-29 Gmg-5 polynucleotides and polypeptides and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34344001P 2001-12-19 2001-12-19
US60/343,440 2001-12-19

Publications (2)

Publication Number Publication Date
WO2003051911A2 WO2003051911A2 (fr) 2003-06-26
WO2003051911A3 true WO2003051911A3 (fr) 2004-06-17

Family

ID=23346124

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2002/004806 WO2003051911A2 (fr) 2001-12-19 2002-10-29 Polypeptides et polynucleotides gmg-5 et utilisations de ceux-ci

Country Status (2)

Country Link
AU (1) AU2002339697A1 (fr)
WO (1) WO2003051911A2 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001055173A2 (fr) * 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Acides nucleiques, proteines et anticorps
WO2001064718A2 (fr) * 2000-03-02 2001-09-07 Lexicon Genetics Incorporated Nouvelles proteines humaines et polynucleotides codant pour lesdites proteines
WO2002055694A2 (fr) * 2001-01-16 2002-07-18 Genset Sa Polynucleotides et polypeptides de genes metaboliques et leurs utilisations

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001055173A2 (fr) * 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Acides nucleiques, proteines et anticorps
WO2001064718A2 (fr) * 2000-03-02 2001-09-07 Lexicon Genetics Incorporated Nouvelles proteines humaines et polynucleotides codant pour lesdites proteines
WO2002055694A2 (fr) * 2001-01-16 2002-07-18 Genset Sa Polynucleotides et polypeptides de genes metaboliques et leurs utilisations

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE GSN [online] 7 January 2002 (2002-01-07), ROSEN C.A. ET AL.: "Human polynucleotide SEQ ID NO:23", XP002244348, Database accession no. AAI99525 *
DATABASE GSP [online] 7 January 2002 (2002-01-07), ROSEN C.A. ET AL.: "Human polypeptide SEQ ID NO:43", XP002244349, Database accession no. AAM99927 *
DATABASE SWALL [online] 1 March 2001 (2001-03-01), WATANABE K. ET AL.: "Hypothetical protein FLJ22569", XP002244351, Database accession no. Q9H667 *

Also Published As

Publication number Publication date
AU2002339697A1 (en) 2003-06-30
AU2002339697A8 (en) 2003-06-30
WO2003051911A2 (fr) 2003-06-26

Similar Documents

Publication Publication Date Title
IL150554A0 (en) Obg3 globular head and uses therof for decreasing body mass
WO2003057144A3 (fr) Changement d'inhibiteurs de la dipeptidyl peptidase iv
AU2002258428A1 (en) Methods for the treatment of metabolic disorders, including obesity and diabetes
IL158590A0 (en) Substituted sulfonamide compounds, process for their use as medicament for the treatment of cns disorders, obesity and type ii diabetes
PL366619A1 (en) Novel, arylsusfonamide compounds for the treatment of obesity, type ii diabetes and cns-disorders
AU2003259706A1 (en) Therapeutic process for the treatment of obesity and associated metabolic disorders
MXPA03008634A (es) Nuevos compuestos de dihidropirimidina ciano sustituidos y su uso para tratar enfermedades.
EP1379236A4 (fr) Traitement des tics, tremblements et troubles afferents
WO2003033534A3 (fr) Polynucleotides et polypeptides ngzipa, ngzipd, pgzipa et pgzipd et utilisations de ceux-ci
WO2003050281A3 (fr) Polynucleotides et polypetides gzip et leurs utilisations
WO2002066505A3 (fr) Polynucleotides et polypeptides gmg-3, gmg-4, et gmg-6 et utilisations associees
WO2002060466A3 (fr) Polynucleotides et polypeptides gssp3 et utilisations de ces derniers
WO2003051911A3 (fr) Polypeptides et polynucleotides gmg-5 et utilisations de ceux-ci
WO2003082915A3 (fr) Polynucleotides polypeptides xcrf et leurs utilisations
AU2002365936A1 (en) Compositions and methods to treat gastrointestinal disorders
WO2001070737A3 (fr) Composes therapeutiques permettant de traiter l'asthme et l'allergie et leurs methodes d'utilisation
WO2002055694A3 (fr) Polynucleotides et polypeptides de genes metaboliques et leurs utilisations
WO2002069689A3 (fr) Polynucleotides et polypeptides gssp4 et utilisations de ces derniers
WO2002058724A3 (fr) Utilisation de lp82 pour traiter les problemes de poids
WO2003095485A3 (fr) Polynucleotides et polypeptides krib et utilisations de ceux-ci dans le traitement de troubles metaboliques
AU2003255843A1 (en) 1,3-thiazolin-4-ones as therapeutic compounds in the treatment of pain
AU2003283938A1 (en) Use of certain compounds in treatment of obesity
WO2001028582A3 (fr) Applications therapeutiques de polypeptides de flint
AU2002357691A1 (en) Methods and compositions to treat pain and painful disorders using 577, 20739 or 57145
AU2002360343A1 (en) Methods and compositions to treat cardiovascular disease using 139, 258, 1261, 1486, 2398, 2414, 7660, 8587, 10183, 10550, 12680, 17921, 32248, 60489 or 93804

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP